Objective: We have recently proposed new diagnostic criteria for high-grade non-small cell neuroendocrine carcinoma, i.e. possible large cell neuroendocrine carcinoma, in biopsy specimens and have started a clinicopathological comparative study of high-grade neuroendocrine carcinomas in an advanced stage. This study aimed to elucidate the usefulness of our diagnostic criteria for inoperable advanced large cell neuroendocrine carcinoma and to know the true incidence of large cell neuroendocrine carcinoma among lung cancers. Methods: We reviewed all cancer lesions (1040 specimens) obtained by transbronchial lung biopsies in our hospital from 2002 to 2009 and selected 38 biopsy specimens that satisfied our diagnostic criteria for high-grade non-small cell neuroendocrine carcinoma. All 38 cases were clinicopathologically investigated and all biopsy specimens were precisely studied for their morphological characteristics. Results: Clinicopathological information about the selected 38 cases was very similar to the clinicopathological characteristics of large cell neuroendocrine carcinoma reported. Of 38 cases, six were at Stage I, II or IIIA, underwent surgery, and the diagnosis was confirmed to be large cell neuroendocrine carcinoma using surgical tumor specimens. In the 38 biopsy specimens, features of neuroendocrine morphology such as organoid nesting, peripheral palisading and rosette formation were not frequent histological features and the majority of tumor cells contained nuclei with a fine chromatin pattern. Mitoses were difficult to find; however, immunohistochemical Ki-67/MIB1 labeling indices were quite useful for evaluating proliferative activity, which ranged from 43.4 to 99.0%. Conclusions: Our study showed the diagnostic potential of using biopsy specimens for large cell neuroendocrine carcinoma, and we herein proposed more simplified diagnostic criteria for possible large cell neuroendocrine carcinoma in practical diagnostic use.
INTRODUCTION
Lung carcinoma is clinically classified into two categories, i.e. small cell lung carcinoma (SCLC) and non-SCLC (NSCLC), with regard to their response to chemoradiotherapy. In 1991, Travis et al. (1) separated a group of high-grade neuroendocrine carcinoma from NSCLC and proposed the new histological category of large cell neuroendocrine carcinoma (LCNEC), which was adopted into the WHO classification in 1999 (2) and retained in the 2004 WHO classification (3) . The main criteria for diagnosing LCNEC are: (1) large cell morphology; (2) high mitotic rate of more than 11 or greater/10 high power fields (HPFs); and (3) the detection of neuroendocrine morphology and immunohistochemical markers (1 -3) . However, it became clear that the clinical features of LCNEC are similar to those of SCLC, and the differential diagnosis between LCNEC and SCLC is quite difficult in some cases (4, 5) . The morphological and clinical similarities of these high-grade neuroendocrine carcinomas are problematic for clinicians and pathologists (1, 4, 5) .
Although the role of chemotherapy in LCNEC is uncertain, Iyoda et al. (6) have reported that patients who received adjuvant chemotherapy had a better prognosis than patients who did not receive adjuvant chemotherapy. Moreover, recent advances in chemotherapy have elucidated that platinumbased adjuvant chemotherapy is effective and significantly improves the survival of patients with LCNEC compared with non-platinum-based adjuvant chemotherapy, suggesting that the initial treatment response of LCNEC to chemotherapy might be similar to that of SCLC (7 -10) . The results of chemotherapy in previous LCNEC studies were obtained by adjuvant chemotherapy after surgery and the diagnosis of LCNEC was made by using resected surgical materials. Not only for resectable LCNEC, but also for non-resectable LCNEC the pathological diagnosis should be made for selecting an appropriate chemotherapy. However, for the diagnosis of LCNEC in a biopsy specimen, the criteria of LCNEC cannot fit because, for example, the mitotic rate cannot necessarily be counted in 10 HPFs in a small necrosis-rich and/or crushed specimen. Thus, for the tumors that can possibly be LCNEC, another criterion for the diagnosis of possible LCNEC is required. Therefore, we focused attention on unresectable high-grade neuroendocrine carcinoma of the lung and aimed to perform a retrospective comparative study in order to know the chemotherapy response of LCNEC and SCLC (9) . This comparative study used biopsy specimens instead of surgical specimens to diagnose LCNEC correctly and to differentiate LCNEC from SCLC. For this purpose, we modified the diagnostic criteria of LCNEC proposed by Travis et al. (1) and proposed new diagnostic criteria of high-grade non-small cell neuroendocrine carcinoma (HNSCNEC), which likely includes most LCNEC (9) .
Using our criteria of HNSCNEC, at least two papers have been published so far and it was concluded that the efficacy of chemotherapy for unresectable LCNEC is comparable with that of SCLC (9, 10) . In this study, we morphologically reviewed all lung biopsy specimens obtained from our hospital from 2002 to 2009 and aimed to improve the criteria of HNSCNEC for better practice with using biopsy specimens and to estimate the true frequency of LCNEC in lung cancer.
PATIENTS AND METHODS

BIOPSY SAMPLES
From September 2002 to December 2009, transbronchial lung biopsy was performed on 1566 patients with lung tumor at Shizuoka Cancer Center Hospital. Using hematoxylin and eosin (H&E)-stained paraffin sections of these biopsy specimens, we histologically reviewed their diagnosis. Of 1566 biopsy cases, 1040 were evaluated to have carcinoma tissue, with a diagnosis of adenocarcinoma (518 cases), squamous cell carcinoma (318 cases), adenosquamous carcinoma (6 cases), SCLC (121 cases), large cell carcinoma (24 cases) and pleomorphic carcinoma (15 cases). Finally, we selected 38 HNSCNECs according to our criteria (9) . Selected from the criteria shown in Table 1 (9), we used the following as essential conditions: no differentiation to squamous cell carcinoma or adenocarcinoma, positive immunostaining for at least one of neuroendocrine markers, large nuclear size with moderate or marked nuclear atypia, a Ki-67/ MIB1 labeling index higher than 40%, and nuclear features (fine chromatin and/or prominent nucleoli) or one of the features of neuroendocrine morphology such as organoid nesting, peripheral palisading, rosettes and/or trabecular architecture.
We excluded poorly differentiated adenocarcinomas by positive periodic acid-schiff-alcian blue mucin staining after diastase digestion. We also excluded squamous cell carcinomas by p63 and keratin 5/6 immunopositivity. The immunohistochemical Ki-67 labeling index was the indicator of high-grade malignancy. Neuroendocrine carcinoma was defined by at least one positive neuroendocrine marker of chromogranin A, synaptophysin and neural cell adhesion molecule (NCAM) and by the neuroendocrine morphology.
Clinical information of these 38 patients was obtained from patients' records (Table 2) .
IMMUNOHISTOCHEMISTRY
For immunostaining, 3 mm-thick sections were prepared from the formalin-fixed and paraffin-embedded tumor specimens. After deparaffinization and blocking of endogenous (2) CT, computed tomography; non-lob, non-lobulated margin; p, peripherally located; rt, right; M, middle lobe; LCNEC, large cell neuroendocrine carcinoma; NED, no evidence of disease; lob, lobulated margin; lt, left; U, upper lobe; DOD, dead of disease; NE, neuroendocrine; AWD, alive with disease; L, lower lobe; c, centrally located; SCLC, small cell lung cancer; LTF, lost to follow-up; MB, main bronchus; TX, primary tumor cannot be assessed by imaging; NX, regional lymph nodes cannot be assessed.
a
The case was examined in ref. (9) .
b
Patient with a history of lung cancer resection 7 years before.
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Biopsy diagnosis of large cell neuroendocrine carcinoma peroxidase activity by 0.3% hydrogen peroxide in methanol, antigen retrieval was carried out using the conventional autoclave method (for 10 min at 1218C) with 0.01 M sodium citrate buffer ( pH 6.0), if necessary. ; DAKO, Â100). The sections were incubated with the primary antibody for 30 min at 378C and followed by the Dako EnVisionþ w detection system (code K4001; Dako Cytomation North America, Inc., CA, USA) and diaminobenzidine as the chromogen to visualize the antigens according to the manufacture's instructions. Negative control slides of each case without first antibody reaction and positive control slides of other normal organ tissue for each antibody were always used and stained simultaneously.
HISTOLOGICAL COMPARISON BETWEEN BIOPSY AND RESECTED SPECIMENS OF SIX RESECTED CASES
Six cases were resected after biopsy because they were in the early stages. We compared the histological findings of these six pairs of biopsy and surgical specimens.
RESULTS
CLINICOPATHOLOGICAL FINDINGS
Clinicopathological information about the 38 HNSCNEC cases used in this study is shown in Table 2 . By computed tomography (CT) imaging of these tumors, 20 tumors (52.6%) showed solid masses with a sharply lobulated margin and 26 tumors (68.4%) were located in the periphery of the lung. The patients' average age was 69.4 (range 56 -89 years). Men predominated (M:F ¼ 34:4) and 35 out of 38 patients were smokers (92.1%). Thirty patients (78.9%) were clinically at Stage IV at diagnosis and 32 (84.2%) were unresectable. Sixteen patients (42.1%) had intrapulmonary metastasis and 23 (60.5%) had distant metastasis at the time of diagnosis, in the brain (13 patients), bone (12 patients), liver (8 patients) and adrenal gland (6 patients). Six tumors at clinical TNM Stage I, II or IIIA were surgically resected and pathologically diagnosed as LCNEC from surgical specimens.
In 38 HNSCNEC cases, serum pro-gastrin releasing peptide (pro-GRP; normal value ,46.0 pg/ml), carcinoembryonic antigen (normal value ,5.0 ng/ml) and neuronspecific enolase (normal value ,10.0 ng/ml) levels were elevated in 13 cases (13/37, 35.1%), 24 cases (24/37, 64.9%) and 27 cases (27/38, 71.1%), respectively.
HISTOLOGICAL AND IMMUNOHISTOCHEMICAL ANALYSES
Initial pathological diagnoses of 38 HNSCNEC biopsy specimens were shown in Table 2 . Eleven cases were finally diagnosed as LCNEC, and non-small cell neuroendocrine carcinoma (case No. 10) was most likely to be LCNEC. Eleven cases were given the diagnosis of high-grade neuroendocrine carcinoma, which seemed to be difficult to differentiate from SCLC. On the other hand, only three cases were diagnosed as SCLC including the combined type. Eleven cases were poorly differentiated carcinoma including large cell carcinoma and adenocarcinoma. These results indicated that two-thirds of HNSCNEC biopsy cases suggested to the pathologists the diagnosis of high-grade neuroendocrine carcinoma and one-third was histologically beyond the scope of neuroendocrine carcinoma.
All HNSCNECs were composed of NSCLC with large nuclei, three times larger than resting lymphocytes and abundant cytoplasm or a low nuclear/ cytoplasmic ratio. As shown in Table 3 , morphological architectural characteristics of LCNEC proposed by Travis et al. (1) were reviewed in the 38 biopsy specimens used in this study. With regard to neuroendocrine morphology, organoid nesting (Fig. 1a) was the most frequently observed structure, but its frequency was only 36.8% of all specimens. Peripheral palisading, rosette formation (Fig. 1b) and trabecular arrangement were observed in only 6 (15.8%), 6 (15.8%) and 5 (13.2%) specimens, respectively. In other morphological characteristics of LCNEC, massive necrosis (Fig. 1c) was seen in 17 biopsy specimens (44.7%). Although most tumor cells contained nuclei with a fine chromatin pattern (Fig. 1d) and faint or visible nucleoli, prominent nucleoli (Fig. 1d, arrows) were observed in about half of all specimens (47.4%). Again, in about half of all biopsy specimens (55.3%), tumor cells had a distinct cell border with intercellular clefts and were often discohesive ( Fig. 1b and d) .
We counted mitotic figures in all 38 tumor specimens. Among them, 11 tumors lacked enough area for mitotic counting, that is to say, 9 HPFs or less. There were 7 tumors 
in which no mitotic figure was found, and another 7 tumors which had a high mitotic rate consistent with 11 or greater per 10 HPFs. In contrast to the mitotic counting, Ki-67/ MIB1 labeling indices could be evaluated in all 38 tumor specimens (Fig. 1e) , which ranged from 41.9 to 99.0% (median: 80.5%). The 7 biopsy specimens with 11 or more mitoses/10 HPFs showed high Ki-67/MIB1 labeling indices from 64.5 to 98.0% (median: 87.3%).
The results of the neuroendocrine immunophenotype in 38 HNSCNECs are shown in Table 4 . NCAM (Fig. 1f) was the most frequently observed neuroendocrine marker (78.9%) among them. There were 12 (31.6%) triple marker-positive cases. No tumor was positive for chromogranin A alone.
As shown in Table 2 , six patients underwent surgery after biopsy, and all resected tumors were pathologically examined and diagnosed as LCNEC. In case No. 1 (Table 2) , for example, the biopsied specimen showed organoid nesting (Fig. 2a) and rosette formation, and tumor cells had abundant cytoplasm and crushed nuclei with a fine chromatin pattern (Fig. 2b) . The immunohistochemistry elucidated NCAM (Fig. 2c ) in addition to a high Ki-67/MIB1 labeling index (Fig. 2d) . This biopsied tumor was pathologically diagnosed as strongly suggestive of LCNEC. As this tumor was peripherally located and clinically showed T1N0M0 (Stage IA), a right middle lobectomy was carried out after biopsy. Morphologically, the resected tumor was composed of large tumor cells with abundant cytoplasm, and showed fine or vesicular nuclei with prominent nucleoli and frequent mitoses (Fig. 3a and b) . There was a necrotic area and tumor cells formed characteristic intercellular clefts and rosettes. Immunohistochemical results were almost identical to those of the biopsy specimen. Finally, the diagnosis of LCNEC was confirmed for this tumor.
Histological details of six biopsy specimens with a confirmed diagnosis of LCNEC are shown in Tables 3 and 5 . Although the sample size was small, morphological characteristics showed a similar tendency to those of other 
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HNSCNECs. Among them, a fine nuclear chromatin pattern was the most frequent finding. These six biopsy specimens had a Ki-67/MIB1 labeling index from 56.6 to 98.7% (median: 70.6%). The comparisons between histological findings of the biopsy specimen and the resected one in each case are shown in Fig. 4 and Table 5 . Fine chromatin in biopsy specimens generally has changed to be rather course chromatin in resected specimens, and peripheral palisading, rosette formation, trabecular arrangement and organoid pattern have become clearly visible in four cases out of six.
DISCUSSION
Using our HNSCNEC criteria (9), we selected 38 cases from all lung biopsy specimens obtained in our hospital from 2002 to 2009. As shown in Table 2 , various clinical characteristics of the 38 cases corresponded well with those of LCNEC cases, which have been already reported by many previous papers using surgically resected LCNEC (1,11 -18) . For example, CT findings have already revealed that LCNEC is peripherally located and has a solid mass with a lobulated margin (19) . In this study, the serum pro-GRP level was elevated in 13 (35.1%) of 37 cases, but no report about the frequency of elevated serum pro-GRP in LCNEC has appeared in the literature. Previous investigations reported that the frequency of the elevated serum pro-GRP level is 68% in SCLC and 4.2% in NSCLC (20) . The frequency of the elevated serum pro-GRP level might be low compared with that of SCLC.
The majority of the 38 cases had pathologically Stage IV disease and many patients died within 1 year after the lung biopsy in this study. LCNEC is a highly malignant neoplasm and previous comparative studies using surgically resected high-grade neuroendocrine carcinoma cases revealed that the prognosis of LCNEC is similar to that of SCLC (16, 18, 21) . Of the 38 cases in this study, 6 were clinical TNM Stage I, II or IIIA, which then underwent surgery after biopsy and the diagnosis was pathologically confirmed as LCNEC using surgically resected tumor specimens. These findings suggest that our HNSCNEC criteria are applicable in practical use for the diagnosis of LCNEC using biopsy specimens. Among high-grade neuroendocrine carcinoma of the lung, the overall clinicopathological features of LCNEC, including unresectable cases, is still uncertain compared with those of SCLC (22) . As it is extremely difficult to make a final diagnosis of LCNEC using only biopsy and/or cytology specimens, the true frequency of LCNEC is undetermined. As the results of a study using surgically resected LCNEC cases, the frequency has been reported to be 1.6-3.1% (7, 11, 13) . If all 38 cases in our study were compatible with LCNEC, the true frequency of LCNEC would be 3.7% (38 out of 1040 biopsies). In the Japanese lung cancer registry study using a large number of surgical and non-surgical cases in 2002, the proportions of adenocarcinoma, squamous cell carcinoma and small cell carcinoma were 56.7, 25.7 and 9.2%, respectively (23). In our biopsy series, these proportions were 49.8, 30.6 and 11.6%, which showed a similar tendency to those of the Japanese lung cancer registry study, although the number is small; therefore, the real frequency of LCNEC might be over 3.7%.
In 1991, Travis et al. (1) proposed a category of LCNEC that was adopted in the WHO classification of lung cancer in 1999 and 2004 (2,3) ; however, these criteria are applicable only to surgically resected specimens, not to biopsy specimens. Biopsy specimens are too small to have enough morphological information and to count the number of mitoses; therefore, we modified the WHO criteria of LCNEC and proposed new criteria for diagnosing LCNEC using biopsy specimens (9) . In our criteria, the immunohistochemical Ki-67/MIB1 labeling index was used instead of the mitotic count. Our study clearly showed that it was very difficult or impossible to count mitoses in small biopsy specimens, but immunohistochemical Ki-67/MIB1 labeling indices could be useful for evaluating the proliferation activity. Fortunately, for 7 of 38 biopsy specimens the number of mitoses could be counted and these specimens were elucidated to have more proliferative activity than biopsy specimens with an impossible mitosis count. In Stage I NSCLCs, the mean Ki-67/MIB1 labeling index is 19.3% (24) , and the prognosis of NSCLC patients is reported to differ between the '20% or higher' group and the 'lower than 20%' group of the Ki67/MIB1 labeling index (25) . When compared with the positivity of the Ki-67/MIB1 labeling index of NSCLC, the labeling index of our biopsy specimens in this study was quite high, which suggests that high proliferative activity is one of the characteristic features of LCNEC (26) .
In the WHO criteria, large cell morphology is one of the most important criteria for LCNEC, such as large tumor cell size with abundant cytoplasm as well as vesicular nuclei and prominent nucleoli (2,3). Our criteria of HNSCNEC (9) also followed the WHO criteria; however, the recognition of this large cell morphology is problematic among pathologists. In previously published papers discussing the interobserver variability of SCLC and LCNEC, the cytologic features of a nuclear/cytoplasmic ratio may be recognized arbitrarily or not quantitatively among diagnostic pathologists (4, 5, 17, 27) . It is also reported that there are borderline cases between LCNEC and SCLC in high-grade neuroendocrine carcinoma (17) . In this study, about one-third of cases were diagnosed as high-grade neuroendocrine carcinoma, but there was a hesitation to diagnose them as LCNEC, because of the cytological similarity to SCLC. Previous studies using surgically resected tumors revealed that LCNEC and SCLC have distinct characteristic morphological features; namely, a large tumor cell size, peripheral palisading and prominent nucleoli Table 5 . Comparison of histological findings between biopsy specimen and resected ones (biopsy/resection) in Cases 1-6 in Table 2 Finding 
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Biopsy diagnosis of large cell neuroendocrine carcinoma are characteristic of LCNEC, and a small cell size, high nuclear/cytoplasmic ratio and fine chromatin pattern are characteristic findings of SCLC (1 -3,17,18) ; however, these morphological features are known to overlap among LCNEC and SCLC (1, 17, 18) . As shown in Table 3 , morphological analysis of 38 biopsy specimens revealed that the incidence of the specimen with a fine chromatin pattern was the highest, and those with intracellular cleft and prominent nucleoli followed in a decreasing order. Therefore, the morphological fine chromatin pattern is not only seen in surgically resected SCLC, but is also a characteristic finding of LCNEC in biopsy specimens as shown in Figs 2 and 4 , Tables 3 and 5 . Even in surgically resected LCNEC, the appearance of tumor cells with fine nuclear chromatin has been Histological comparison between biopsy and resected specimens in two of the resected six cases. In Case 3 (a -d), the biopsy specimen shows fine chromatin architecture with visible nucleoli and an obscure rosette pattern (a, H&E, Â20; b, H&E, Â40). However, in the resected specimen, a large number of rosettes are observed (c, H&E, Â20; d, H&E, Â40). The chromatin is coarse and the cytoplasm is abundant. In Case 5 (e -h), the biopsy specimen is crushed and neither the neuroendocrine structure nor nucleoli can be recognized (e, H&E, Â20; f, H&E, Â40). However, in the resected specimen, peripheral palisading, organoid nesting and nucleoli are clearly observed (g, H&E, Â10; h, H&E, Â40).
Jpn J Clin Oncol 2013;43(3) 301 noted (1,18). As our resected cases were found to show a chromatin pattern changed from the fine pattern in the biopsy specimen to a coarse or vesicular pattern (Fig. 4 and Table 5 ), it is supposed that the different fixative conditions might have some effects on the chromatin morphology of tumor cells. The greatest difference might be due to a rapid start and full immersion in formalin soon after taking a biopsy specimen, in contrast to a delayed start and immersion in a relatively small ratio of fixative amount/specimen size for a resected specimen, resulting in fine chromatin morphology and a coarse or vesicular one, respectively. Furthermore, as another histological finding, intercellular cleft might reflect poor intercellular connection and might be one of the characteristics of LCNEC. In LCNEC, the appearance of neuroendocrine morphology such as organoid nesting, palisading, rosette and trabeculae has been frequently observed and their frequencies are reported to be 90.9, 59.1, 72.7 and 31.8%, respectively (18) . In contrast, Figs 2 and 4 revealed that the neuroendocrine morphology was relatively difficult to recognize in biopsy specimens. This may be attributed to the small size of specimens. Therefore, immunohistochemical detection of a neuroendocrine marker is a more reliable method to identify the neuroendocrine features of biopsy specimens. In a previous report, synaptophysin was frequently positive at the rate of 77% in LCNEC, and chromogranin A and CD56 followed (17) . In our study, NCAM was the most frequently immunopositive neuroendocrine marker and chromogranin A followed after synaptophysin. This may be explained by the difference of the pattern of immunostaining because NCAM tends to stain tumor cells diffusely compared with chromogranin A or synaptophysin. For immunohistochemical evaluation of neuroendocrine features in both surgically resected or biopsy samples, immunohistochemistry using three neuroendocrine markers is necessary.
Although the cases in the early stage can be resected and histologically confirmed, the cases in an advanced stage should receive chemotherapy without histologically examining resected specimens. Then the criteria of HNSCNEC may give the chance for lesions that have the possibility of being LCNEC to be treated as inoperable advanced probable LCNEC cases. For this reason some papers have reported that the clinical efficacy of chemotherapy for LCNEC is comparable with that for SCLC (7 -10); the diagnosis of 
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Biopsy diagnosis of large cell neuroendocrine carcinoma HNSCNEC as a surrogate of LCNEC or as a probable LCNEC would help these lesions to receive more appropriate therapy. When the criteria of HNSCNEC work, the number of patients who receive chemotherapy for LCNEC, comparable to that for SCLC, might increase by 0.6 -2.1% of the number of all lung carcinomas. This estimation is according to the comparison between the reported frequency (1.6 -3.1%) of LCNEC (7, 11, 13) and the incidence (3.7%, 38 out of 1040 lung biopsies positive for cancer) of HNSCNEC in our hospital, which has already been discussed. WHO criteria (3), our previous criteria (9) and our new criteria have three common essential points as indicated in the upper one-third of Table 6 ; and there is one more essential point on proliferating activity. In our new criteria, the Ki67/MIB1 labeling index is adopted instead of mitotic counting. Then our new criteria can be shown as in Table 7 . Summarizing the data obtained in this study using biopsy specimens, we simplified our previous criteria for HNSCNEC and proposed new diagnostic criteria suitable for possible LCNEC (28) . In the new criteria (Table 7) , the major points are essential for diagnosing LCNEC using biopsy specimens. In addition to the major points, the findings due to additional minor points would increase the possibility of an LCNEC diagnosis. We expect these new criteria to be used in routine surgical pathology and to facilitate the clinicopathological study of high-grade neuroendocrine carcinoma, especially LCNEC.
